-+ 0.00%
-+ 0.00%
-+ 0.00%

Tectonic Therapeutic reports favorable Phase 1a results for TX2100 in HHT program

PUBT·09/29/2026 12:09:17
Tectonic Therapeutic reports favorable Phase 1a results for TX2100 in HHT program
  • Tectonic Therapeutic reported favorable topline Phase 1a results for TX2100 in healthy volunteers, supporting advancement into HHT patient studies.
  • The study showed TX2100 was generally safe and well tolerated, with no serious safety signals reported in the single-dose cohorts.
  • Detailed Phase 1a safety, tolerability, pharmacokinetic, and anti-drug antibody results will be presented at the CureHHT conference on Oct. 12-16, 2026.
  • FDA granted Fast Track designation for TX2100 in HHT, strengthening the program’s regulatory path.
  • Plans call for an open-label Phase 1b trial to start by year-end 2026, with a placebo-controlled Phase 2 trial targeted for early 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tectonic Therapeutic Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290800PRIMZONEFULLFEED9835535) on September 29, 2026, and is solely responsible for the information contained therein.